Targeted deployment of twice-yearly lenacapavir as PrEP for pregnant and breastfeeding women in high-incidence sub-Saharan African districts could significantly reduce vertical HIV transmission at a net cost of US$8,500 per acquisition averted. According to a modelling study by Anna Yakusik of UNAIDS and colleagues, this approach is far more cost-effective than universal rollout, which carries a cost of US$85,000 per acquisition averted.
How Targeted Deployment Improves Cost-Effectiveness
The modelling study, published in the Journal of the International AIDS Society, suggests that resources should be directed toward specific high-incidence districts rather than broad, universal coverage. Researchers found that focusing on geographic areas with the highest risk profiles allows for a more efficient allocation of funding and medical supplies. By limiting the scope of lenacapavir distribution to these priority regions, the net cost per HIV acquisition averted drops by 90% compared to a universal rollout strategy.
Lenacapavir is an injectable form of pre-exposure prophylaxis (PrEP) that requires administration only twice per year, offering a potential alternative to daily oral pills for women in high-incidence regions.
What Role Does Lenacapavir Play in Prevention Programs?
Authors of the study emphasize that lenacapavir is designed to complement existing public health infrastructure rather than replace it. Strengthening current programs aimed at preventing vertical transmission—the transmission of HIV from mother to child during pregnancy, birth, or breastfeeding—remains a foundational priority. According to the research team, the drug functions as an additional tool to bolster maternal and paediatric health outcomes when integrated into established healthcare systems.
How Does This Compare to Universal Rollout Strategies?
The disparity in cost-effectiveness between targeted and universal distribution is stark. Data from the UNAIDS-affiliated modelling study highlights the following comparison:
- Targeted Deployment: US$8,500 per HIV acquisition averted.
- Universal Rollout: US$85,000 per HIV acquisition averted.
Frequently Asked Questions
What is lenacapavir?
Lenacapavir is a long-acting injectable medication used as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV. It is administered twice a year.
Why is targeted deployment recommended over universal rollout?
According to the Journal of the International AIDS Society study, targeted deployment in high-incidence districts is significantly more cost-effective, costing US$8,500 per acquisition averted compared to US$85,000 for universal rollout.
Does this study suggest replacing current HIV programs?
No. The authors explicitly state that lenacapavir should serve as a complement to existing programs, not as a substitute for strengthening current efforts to prevent vertical HIV transmission.
For more insights on global health trends and HIV prevention, subscribe to our newsletter or browse our archive of public health research. Have a question about how these models are developed? Let us know in the comments below.
Worth a look
